Corona Remedies Limited, a prominent pharmaceutical company, has witnessed an overwhelming response from investors on the second day of bidding for its ₹655. 37 crore Initial Public Offering (IPO). The issue, priced in a band of ₹1,008 to ₹1,062 per share, has been subscribed 5. 28 times overall as per the latest available figures. This strong subscription is largely attributed to significant participation from both retail individual investors (RIIs) and non-institutional investors (NIIs), reflecting strong market confidence in the company's prospects.
Subscription Status Breakdown
By the end of the second day, the subscription figures for Corona Remedies IPO highlighted a keen interest across various investor categories. The overall subscription stood at an impressive 5, while 28 times. Breaking down the figures, the non-institutional investors (NIIs) segment showed exceptional enthusiasm, subscribing to their allocated portion by 13, while 74 times. This high subscription rate from NIIs typically indicates strong demand from high-net-worth individuals (HNIs) and corporate entities. Retail individual investors (RIIs) also participated actively, with their portion being subscribed 4. 67 times, demonstrating broad appeal among smaller investors. In contrast, the Qualified Institutional Buyers (QIBs) segment has seen a. Relatively subdued response so far, with a subscription of only 0. 11 times. This is a common trend, as institutional investors often place their bids closer to the closing date, suggesting that the final subscription numbers for QIBs could still see a significant uptick.
Accelerated Bidding on Day Two
Compared to the first day of the IPO, which saw an overall subscription of 62%, the second day witnessed a significant acceleration in bidding, particularly from NIIs and RIIs. The NII segment's subscription jumping to 13. 74 times and RIIs to 4, while 67 times underscores the growing positive sentiment surrounding the IPO. This surge in interest on the second day often occurs as investors assess initial market reactions and then commit their bids, while while the QIB segment's subscription remains low, it's anticipated to pick up substantially on the final day, as large institutional investors typically strategize and place their substantial bids towards the end of the bidding period. This pattern suggests that the overall subscription rate is likely to climb further before the IPO closes.
The Corona Remedies IPO commenced on December 8 and is scheduled to close on December 10, 2025. The price band for the shares has been set between ₹1,008 and ₹1,062 per share, with a lot size comprising 14 shares. The allotment of shares is expected to take place on December 11, followed by the listing of the shares on both the BSE and NSE on December 15, while it's important for investors to note that this IPO is entirely an Offer For Sale (OFS). This means that the company itself won't receive any proceeds from the sale of shares, while instead, the funds generated from the sale will go to the existing promoters and shareholders who are offloading their stakes. This structure places the focus squarely on the company's current valuation and future growth potential for prospective investors.
Key IPO Details and Timeline
Potential for Listing Gains
The strong momentum of Corona Remedies shares in the unlisted market further fuels investor excitement. According to unlisted market tracking websites, the Grey Market Premium (GMP) for Corona Remedies IPO is currently ranging between ₹257 and ₹290 per share, while this GMP indicates a potential listing premium of approximately 27. 31% over the upper end of the price band (₹1,062). With this premium, the shares are projected to list around ₹1,352. This suggests that initial investors could realize substantial profits upon listing,. Making the IPO an attractive proposition for those seeking quick returns. The Grey Market Premium is often considered a reliable indicator of market. Sentiment and the potential performance of a stock on its listing day.
Investor Opportunity and Outlook
The solid subscription figures and the encouraging Grey Market Premium for the Corona Remedies IPO present a promising opportunity for investors. The company's position in the pharmaceutical sector and its financial performance have clearly resonated with the market. The heavy participation from non-institutional and retail investors indicates a positive outlook on the company's future prospects. The potential listing premium of 27. 31% serves as a significant incentive for investors looking for immediate gains. While the final bids from Qualified Institutional Buyers are yet to come in, which will further influence the ultimate subscription numbers,. The overall sentiment around Corona Remedies IPO remains highly positive, positioning it as an appealing investment choice in the current market scenario.
